PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Identifies how quickly the company is scaling its balance sheet (via acquisitions, expansions, or debt). Strong growth, accompanied by sound fundamentals, can support long-term intrinsic value—while disproportionate debt expansion or bloated intangible assets can signal elevated risk.
-15.30%
Both companies show declining cash positions (-15.30% vs AGEN's -7.51%). Seth Klarman would examine if this reflects broader market conditions or operational challenges.
No Data
No Data available this quarter, please select a different quarter.
-15.30%
Similar yoy growth to AGEN's -14.08%. Walter Schloss would note comparable liquidity expansions. Examine capital usage strategies.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-15.91%
1.25-1.5x AGEN's -12.79%. Bruce Berkowitz checks if strong current asset growth is used effectively.
-12.74%
Below half AGEN's 2.12%. Michael Burry sees potential underinvestment risk unless there's a valid reason (asset-light model).
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
0.02%
Less than half of AGEN's -5.32%. David Dodd sees fewer expansions in non-core assets. Possibly a simpler focus.
-1.64%
Below half of AGEN's 26.61%. Michael Burry might suspect stagnation or lack of resources for expansions.
No Data
No Data available this quarter, please select a different quarter.
-15.58%
≥ 1.5x AGEN's -7.28%. David Dodd notes a larger balance sheet expansion. Confirm it's not overleveraged.
72.22%
Above 1.5x AGEN's 20.35%. Michael Burry questions if payables are being stretched to avoid short-term borrowing.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-79.94%
Exceeding 1.5x AGEN's -47.54%. Michael Burry suspects ballooning short-term obligations vs. competitor.
32.21%
Above 1.5x AGEN's 3.73%. Michael Burry sees a red flag for liquidity risk vs. competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
32.21%
Above 1.5x AGEN's 6.65%. Michael Burry sees a potential leverage warning sign.
0.06%
Less than half of AGEN's 1.97%. David Dodd sees fewer share issuances vs. competitor.
-3.27%
Similar yoy to AGEN's -3.53%. Walter Schloss sees parallel earnings retention vs. competitor.
0.51%
Less than half of AGEN's -5.38%. David Dodd sees fewer intangible or market-driven swings than competitor.
No Data
No Data available this quarter, please select a different quarter.
-24.85%
0.5-0.75x AGEN's -46.95%. Martin Whitman is wary of lagging equity growth vs. competitor.
-15.58%
≥ 1.5x AGEN's -7.28%. David Dodd sees faster overall balance sheet growth than competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
15.30%
Less than half of AGEN's 31.55%. David Dodd sees better deleveraging or stronger cash buildup than competitor.